Kenneth R. Chien
Kenneth Randall Chien | |
---|---|
Nationality | American |
Alma mater | |
Known for |
|
Parent | Luther Chien (father) |
Awards | Pasarow Award (1996) |
Scientific career | |
Fields |
|
Institutions |
|
Kenneth R. Chien (born 1951)
Education
Kenneth's father Luther was born in China and escaped the second world war. He became a
Career and research
Chien became a member of the faculty at the University of California at San Diego,
Moderna involvement
While working at Harvard, Chien was approached by Derrick Rossi, a colleague at the Harvard Stem Cell Institute, about co-founding a newco, based on findings in the Rossi lab on reprogramming stem cells with mRNA.[5][19] This eventually turned into the medical research company Moderna Therapeutics, co-founded by Rossi, Chien and Bob Langer under the aegis of Flagship VentureLabs in 2011.[20] In 2011, the Chien Lab made the discovery of the high efficiency expression of VEGF mRNA in heart muscle, resulting in a patent on the discovery that triggered mRNA towards therapeutic applications.[18][21] In 2013, Chien and his associates documented the ability of VEGF mRNA for coronary vascular regeneration and to reverse the onset of heart dysfunction, thereby opening the potential of were researching the possibility of using synthetic messenger RNA (mRNA) to produce therapeutic desired effects in a patient's muscle cells:
“What we have shown is that muscle cells take up this synthetic mRNA and will express almost any protein quickly. The technology will allow an intense, focused, one‐time application to drive a therapeutic effect that might have a long‐lasting effect by affecting, expanding and redirecting the fate of rare native tissue progenitors that are normally mobilized during injury and usually contribute to scar tissue.” [16] At Karolinska, the Chien lab documented the ability to generate large numbers of human Islet heart progenitor cells from human embryonic stem cells, which resulted in a partnership with Astrazeneca to move the project toward clinical application.[22][23]
In February 2019, AstraZeneca and the Chien lab reported the first in human study of an mRNA therapeutic, noting reversal of vascular dysfunction in diabetic patients by VEGF mRNA.[24]
Awards and honors
- American Physiological Society - Walter B. Cannon Award - Annual Award For Outstanding Investigator in Physiological Sciences[25]
- Robert J. and Claire Pasarow Foundation - Pasarow Foundation Award[26]
- Austrian Academy of Sciences - Foreign Member Elect[8]
- Norwegian Academy of Sciences - Foreign Member Elect[7]
- University of Edinburgh - Honorary Doctorate of Science[9]
- UCSD School of Medicine - American Heart Association Chair in Cardiovascular Research[27]
- Harvard University - Sanders Endowed Chair in Medicine and Cell Biology[28]
- Swedish Research Council - Distinguished Professorship[29]
- European Research Council (ERC) - Advanced Research Grant Award[30]
- Knut and Alice Wallenberg - Research Grant Award[31]
Selected publications
- "PPARγ is required for placental, cardiac, and adipose tissue development", Y Barak, MC Nelson, ES Ong, YZ Jones, P Ruiz-Lozano, KR Chien, ..., Molecular cell 4 (4), 585–595, (1999)
- "Postnatal isl1+ cardioblasts enter fully differentiated cardiomyocyte lineages", KL Laugwitz, A Moretti, J Lam, P Gruber, Y Chen, S Woodard, LZ Lin, ..., Nature 433 (7026), 647–653, (2005)
- "Signaling pathways for cardiac hypertrophy and failure", JJ Hunter, KR Chien, New England Journal of Medicine 341 (17), 1276–1283, (1999)
- "Multipotent embryonic isl1+ progenitor cells lead to cardiac, smooth muscle, and endothelial cell diversification", A Moretti, L Caron, A Nakano, JT Lam, A Bernshausen, Y Chen, Y Qyang, ..., Cell 127 (6), 1151–1165, (2006)
- "Cardiac muscle cell hypertrophy and apoptosis induced by distinct members of the p38 mitogen-activated protein kinase family", Y Wang, S Huang, VP Sah, J Ross, JH Brown, J Han, KR Chien, Journal of Biological Chemistry 273 (4), 2161–2168, (1998)
- "Epicardial progenitors contribute to the cardiomyocyte lineage in the developing heart", B Zhou, Q Ma, S Rajagopal, SM Wu, I Domian, J Rivera-Feliciano, ..., Nature 454 (7200), 109–113, (2008)
- "Regulation of cardiac gene expression during myocardial growth and hypertrophy: molecular studies of an adaptive physiologic response", KR Chien, KU Knowlton, S Chien, The FASEB Journal 5 (15), 3037–3064, (1991)
- "ErbB2 is essential in the prevention of dilated cardiomyopathy SA Crone", YY Zhao, L Fan, Y Gu, S Minamisawa, Y Liu, KL Peterson, ..., Nature medicine 8 (5), 459–465, (2002)
- "MLP-deficient mice exhibit a disruption of cardiac cytoarchitectural organization, dilated cardiomyopathy, and heart failure", S Arber, JJ Hunter, J Ross Jr, M Hongo, G Sansig, J Borg, JC Perriard, ..., Cell 88 (3), 393-403 (1997)
- "Enhanced myocardial function in transgenic mice overexpressing the beta 2-adrenergic receptor", CA Milano, LF Allen, HA Rockman, PC Dolber, TR McMinn, KR Chien, ..., Science 264 (5158), 582–586, (1994)
External links
References
- ^ "Utenlandske medlemmer" (in Norwegian). Norwegian Academy of Science and Letters. Archived from the original on 15 July 2007. Retrieved 27 December 2021.
- ^ a b "kenneth chien". scholar.google.com.
- ^ a b "| Karolinska Institutet". ki.se.
- ^ "Kenneth Chien". LinkedIn.
- ^ a b Xconomy: https://xconomy.com/boston/2012/12/06/moderna-40m-in-tow-hopes-to-reinvent-biotech-with-new-protein-drugs/
- ^ "In quest for vaccine, US makes 'big bet' on company with unproven technology". CNN.
- ^ a b "Group 7: Medical sciences". The Norwegian Academy of Science and Letters.
- ^ a b "Prof. KENNETH R. CHIEN , M.D. PH.D." Austrian Academy of Sciences.
- ^ a b "Professor Kenneth Chien". The University of Edinburgh.
- ^ Meyer, Mahlon (2021-09-02). "Moderna co-founder Kenneth Chien finds silver lining".
- ^ "Ken Chien moving to Mass General". Medscape.
- ^ Chien, Kenneth R. (March 31, 1982). "Biochemical events in irreversible, ischemic liver cell injury /". librarysearch.temple.edu.
- ^ "Kenneth Chien". EQT Profile.
- ^ "UCSD Profiles: Kenneth Chien". UCSan Diego.
- ^ a b c "Kenneth R. Chien, MD, PhD". www.camasc.org.
- ^ PMID 23938329.
- ^ "Doximity: KennethRandallChienMD".
- ^ a b "Kenneth R. Chien Inventions, Patents and Patent Applications - Justia Patents Search". patents.justia.com.
- ^ Elton, Catherine (February 26, 2013). "Does Moderna Therapeutics Have the Next Big Thing in Medicine?".
- ^ "Moderna Closes $450 Million Financing to Support Growth of Messenger RNA Therapeutics™ Platform across Diverse Therapeutic Areas | Fierce Biotech".
- ^ "Meet the company that has just begun testing a coronavirus vaccine in the United States". Science Magazine.
- ^ "AstraZeneca, SWIBCo Launch Stem Cell Cardiovascular Therapy Collaboration". Genetic Engineering and Biotechnology news. 7 May 2018.
- S2CID 4569919.
- S2CID 256642553.
- ^ "How to Fix a Broken Heart". The Science Network.
- ^ "Pasarow Awards honor Knusdon, Chien, and Prusiner". USC News. May 9, 1996.
- ^ "List of Endowed Chairs at UC San Diego". blink.ucsd.edu.
- ^ "Community (11/6/09)". hms.harvard.edu.
- ^ "50 miljoner kronor var till tre KI-professorer | Karolinska Institutet Nyheter". nyheter.ki.se.
- ^ "ERC Advanced Grant to three researchers at Karolinska Institutet | Karolinska Institutet Nyheter". news.ki.se.
- ^ "Knut och Alice Wallenbergs Stiftelse ger 175 miljoner kronor till forskning vid Karolinska Institutet | Karolinska Institutet Nyheter". nyheter.ki.se.